 NeuroBo Pharmaceuticals, Inc. Nasdaq: NRBO, a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today reported that the company is scheduled to join the broad-market Russell 3000 and Microcap Indexes at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions posted June 15. 